Prof jun Li | Innovative Leadership | Best Researcher Award

Prof jun Li | Innovative Leadership | Best Researcher Award

Changzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, China

Profile

Orcid

Early Academic Pursuits đź“š

Jun Li’s journey into the field of medicine was marked by his unwavering dedication to Traditional Chinese Medicine (TCM). As a graduate of Nanjing University of Chinese Medicine, he excelled academically, earning the prestigious title of “Outstanding Graduate.” This recognition reflected his commitment to understanding the intricate balance of traditional practices and modern medical advancements. During his studies, Jun Li demonstrated a keen interest in exploring minimally invasive techniques and their integration with TCM principles, setting a solid foundation for his professional career.

Professional Endeavors 🏥

After completing his academic training, Jun Li joined the esteemed Changzhou TCM Hospital Affiliated to Nanjing University, where he rose to the position of Associate Chief Physician. In this role, he has been instrumental in pioneering advancements in spinal health and minimally invasive procedures. His clinical expertise and commitment to patient care have made him a trusted name in his community. Beyond his clinical work, Jun Li actively participates in medical research and serves as a mentor, guiding young physicians and promoting innovation within the hospital.

Contributions and Research Focus 🔬

Jun Li’s research focuses on integrating modern medical technologies with the principles of Traditional Chinese Medicine to create minimally invasive solutions for spinal conditions. As a member of the Spinal Minimally Invasive Expert Committee of the Chinese Society of Traditional Chinese Medicine, he collaborates with fellow experts to develop cutting-edge techniques that prioritize patient safety and recovery. His contributions extend to the Integrated Development Branch of Traditional Chinese Medicine under the China Future Research Association, where he helps shape the future direction of TCM research and practice.

Accolades and Recognition 🏆

Jun Li’s contributions have earned him numerous accolades. He was selected as one of the first young talents for the “361 Talent Training Project” of Changzhou City, highlighting his potential as a future leader in TCM. He has received the “Health Commission Award of Changzhou City” multiple times, a testament to his dedication and excellence in healthcare. Furthermore, Jun Li was honored as one of the “Top Ten Young Physicians of Changzhou Traditional Chinese Medicine Hospital,” reflecting his outstanding clinical skills and commitment to the well-being of his patients.

Impact and Influence 🌍

Through his clinical practice, research, and leadership, Jun Li has significantly influenced the field of Traditional Chinese Medicine. His work in spinal health and minimally invasive techniques has not only improved patient outcomes but also inspired a new generation of physicians to adopt innovative approaches. As an active participant in national and regional committees, he fosters collaboration among healthcare professionals, ensuring that the integration of modern and traditional practices continues to advance.

Legacy and Future Contributions 🌟

Jun Li’s contributions to medicine and his community have left a lasting legacy. His focus on combining innovation with tradition exemplifies the potential of TCM in addressing modern healthcare challenges. Looking ahead, Jun Li aims to further expand his research, enhance educational initiatives, and continue shaping the future of healthcare. His work serves as an inspiration to those striving to bridge the gap between time-honored practices and cutting-edge advancements.

Jun Li’s dedication, achievements, and vision make him a distinguished figure in the realm of Traditional Chinese Medicine, setting a benchmark for excellence and innovation in healthcare.

 📝Notable Publications

Comparison of the effects between arthroscopic transtibial pullout technique and all-inside repair in the treatment of medial meniscus posterior root tears

  • Authors: Li J, Shen P, Zou T, Min W, Qu Y, Xie Z, Wei C
  • Journal: Journal of Orthopaedics
  • Year: 2024

Epimedin A inhibits the PI3K/AKT/NF-ÎşB signalling axis and osteoclast differentiation by negatively regulating TRAF6 expression

  • Authors: Li Jun, Wei JJ, Wu CH, Zou T, Zhao H, Huo TQ, Wei CJ, Yang T
  • Journal: Molecular Medicine (Cambridge, Mass.)
  • Year: 2024

Comparison of the effects between oblique lateral interbody fusion (OLIF) and minimally invasive transforaminal interbody fusion (MIS-TLIF) in the treatment of adult degenerative lumbar scoliosis

  • Authors: Jun L, Zou T, Wei JJ, Huo T, Min W, Wei C, Zhao H
  • Journal: Journal of Orthopaedics
  • Year: 2024

FGD5-AS1 facilitates the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells via targeting the miR-506-3p/BMP7 axis

  • Authors: Li J, Wu X, Yao Shi, Zhao H
  • Journal: Journal of Orthopaedic Surgery and Research
  • Year: 2021

Hirudin protects against isoproterenol-induced myocardial infarction by alleviating oxidative via an Nrf2-dependent manner

  • Authors: Zhang H, Chen H, Li J, Bian Y, Song Y, Li Z, He F, Liu S, Tsai Y
  • Journal: International Journal of Biological Macromolecules
  • Year: 2020

 

 

Prof Dr. Shankar Prinja | Strategic Leadership | Best Researcher Award

Prof Dr. Shankar Prinja | Strategic Leadership | Best Researcher Award

Post Graduate Institute of Medical Education and Research, Chandigarh, India 

Profile 

Orcid 

🏫 Early Academic Pursuits

Dr. Shankar Prinja embarked on his academic journey with a strong foundation in medicine. He earned his MBBS degree in 2002 from Gandhi Medical College in Bhopal, Madhya Pradesh, India. His academic excellence was evident early on, as he secured a Gold Medal for achieving first position in Barkatullah University during his Final Part-I MBBS. His passion for preventive and social medicine led him to pursue an MD in Community Medicine at Pt. BD Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India, which he completed in 2005. Further solidifying his expertise, he obtained the Diplomate National Board (DNB) certification in 2006 from the National Board of Examination, New Delhi, India.

Recognizing the importance of health policy and planning in public health, Dr. Prinja expanded his academic horizons internationally. He pursued an MSc in Health Policy, Planning, and Financing in 2009, a joint program between the London School of Hygiene and Tropical Medicine and the London School of Economics and Political Science in the UK. His performance in this rigorous program was exceptional, earning him a distinction from the London School of Economics and Political Science.

đź’Ľ Professional Endeavors

Dr. Prinja’s professional career is marked by a deep commitment to health economics and public health. His journey began as a Senior Resident in Community Medicine at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, where he continued to grow and evolve in various capacities. He quickly progressed from Research Scientist-II (Medical) to Health Economist and then to Assistant Professor of Health Economics.

By 2011, Dr. Prinja was appointed Assistant Professor of Health Economics at PGIMER, and his career trajectory continued to rise. He was promoted to Associate Professor in 2014, Additional Professor in 2017, and eventually Professor of Health Economics in 2021. His role at PGIMER has been instrumental in shaping health policy and economics education in India. He has also served as the Coordinator of the State Training Resource Centre, contributing to the capacity-building of public health professionals.

Dr. Prinja’s expertise has been sought by various national and international organizations. He served as Executive Director at the National Health Authority, Government of India, from January 2022 to January 2023. He has also been a short-term consultant for the World Bank Group on multiple occasions, providing his expertise on health economics and policy.

🧠 Contributions and Research Focus

Dr. Prinja’s research interests lie at the intersection of health economics, policy planning, and financing. His work focuses on improving the efficiency and effectiveness of health systems, particularly in resource-limited settings. He has contributed significantly to the understanding of cost-effectiveness in health interventions, which is crucial for policy formulation in countries like India.

He has been an active member of several technical groups and committees that influence health policy in India. Notably, he is a member of the National Technical Advisory Group on Immunization (NTAGI) and chairs the Vaccine Cost-effectiveness Analysis Sub-group, where his work has been critical in guiding India’s immunization policies. His involvement in the Ministry of Health and Family Welfare’s various task forces, including those on COVID-19 research and the National Health Accounts, highlights his integral role in shaping India’s public health strategies.

Dr. Prinja’s work has had a global impact as well. He is a member of the Technical Group of the COVID-19 Multi-Model Comparison Collaboration (CMCC) of the WHO and World Bank. His research contributions extend to multilateral groups such as the Cost-Effectiveness Data Across Settings (CEDAS) working group of the WHO’s DECIDE Hub.

🏆 Accolades and Recognition

Dr. Prinja’s contributions to public health and health economics have been recognized through numerous prestigious awards and honors. In 2021, he was awarded the Prof MK Seshadri award by the Indian Council of Medical Research, a testament to his impactful research. The same year, he received the Vijay Narain Award from the Indian Association of Preventive and Social Medicine.

Earlier in his career, Dr. Prinja was recognized with the Prof. BC Shrivastav Foundation Award by the Indian Council of Medical Research in 2018. His consistent high-quality research has earned him certificates of appreciation during PGIMER’s Annual Research Day in 2013, 2014, 2018, 2021, 2022, and 2024. Internationally, he was graded ‘A’ (Excellent) at the International Doctoral course in Health Economics and Policy on “Inequalities in Health and Health Care” by the Swiss Schools of Public Health + (SSPH+), Geneva, Switzerland in 2010.

🌍 Impact and Influence

Dr. Prinja’s work has had a profound impact on public health policy and health economics, not just in India but globally. His research has informed critical policy decisions, particularly in the context of immunization and healthcare financing. His role in various advisory boards, including the Tufts-CEVR Global Health Advisory Board and the Health Economics, Management and Policy Program at Newcastle Business School, University of Newcastle, Australia, underscores his influence in the field.

His contributions during the COVID-19 pandemic, particularly through his membership in the WHO and World Bank’s CMCC, were pivotal in guiding global health responses. His work on cost-effectiveness and health system strengthening continues to shape the discourse on sustainable healthcare in developing countries.

🌟 Legacy and Future Contributions

Dr. Shankar Prinja’s legacy is marked by his unwavering commitment to improving public health through rigorous research and impactful policy work. His career has been a blend of academic excellence, professional dedication, and influential research that has left a lasting impact on health systems in India and beyond.

Looking ahead, Dr. Prinja is poised to continue his contributions to global health policy, with a focus on sustainable and equitable healthcare solutions. His ongoing research and involvement in international health economics will undoubtedly continue to shape the future of public health, ensuring that his influence endures for generations to come.

Publications 

Integrating Economic and Health Evidence to Inform Covid-19 Policy in Low- and Middle-Income Countries

Authors: [Not Provided]

Journal: Wellcome Open Research

Year: 2022

What is the Out-of-Pocket Expenditure on Medicines in India? An Empirical Assessment Using a Novel Methodology

Authors: Shankar Prinja

Journal: Health Policy and Planning

Year: 2022

Burden of Group A Streptococcal Pharyngitis, Rheumatic Fever, and Rheumatic Heart Disease in India: A Systematic Review and Meta-Analysis

Authors: Shankar Prinja

Journal: Indian Journal of Pediatrics

Year: 2022

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women

Authors: Shankar Prinja

Journal: Applied Health Economics and Health Policy

Year: 2022

Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set

Authors: Shankar Prinja

Journal: Value in Health

Year: 2022